NEW YORK (GenomeWeb News) – French genome engineering company Cellectis said yesterday that it will collaborate with the French National Institute for Agricultural Research, or INRA, to investigate the use of Cellectis' technology in a range of applications.

Under the five-year, non-exclusive agreement, Cellectis and INRA will investigate the potential of a range of technologies in which Cellectis specializes, including reverse genetics, homologous recombination, and gene targeting, in applications such as cell biology and plant and animal biotechnology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.